Publications

Skip to main content

View the latest BOT/BAL presentation from ESMO-GI

Publications

Publishing the Frontiers of Immuno-Oncology

Spotlight Publication

Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)

Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors

Oct 17, 2025

,

Gordon et al.

ESMO

Colorcectal

Pan Tumor

View Publication

Agenus Inc.
3 Forbes Road
Lexington, MA 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200

Our Science

Pipeline

Publications

Clinical Trials

Immunotherapy

About BOT + BAL

Company

Our History

Our Team

Careers

Partners

Access

Patient Access

Contact Medical Affairs

Resources

Press Releases

In the News

Patient Resources

FAQs

Investors

Investor Overview

Events

Financial Information

Opt-out preferences Cookie Policy Terms and Conditions of Use Privacy Policy Community Guidelines Access to Investigational Medicines Policy Report Adverse Event Investor Portal

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

Publishing the Frontiers of Immuno-Oncology

Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors

Separation and Characterization of Saponins With Adjuvant Activity From Quillaja Saponaria Molina Cortex.

Synthetic Malaria Peptide Vaccine Elicits High Levels of Antibodies in Vaccinees of Defined HLA Genotypes.

T-cell Responses Against Tyrosinase 368-376(370D) Peptide in HLA*A0201+ Melanoma Patients: Randomized Trial Comparing Incomplete Freund's Adjuvant, Granulocyte Macrophage Colony-Stimulating Factor, and QS-21 as Immunological Adjuvants.

Using Big Data and Machine Learning to Understand T cell Dysfunction in Human Tumors.